Kovack Advisors Inc. Purchases 141 Shares of Amgen Inc. (NASDAQ:AMGN)

Kovack Advisors Inc. raised its position in Amgen Inc. (NASDAQ:AMGN) by 5.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,983 shares of the medical research company’s stock after purchasing an additional 141 shares during the period. Kovack Advisors Inc.’s holdings in Amgen were worth $859,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in AMGN. BIP Wealth LLC boosted its position in shares of Amgen by 2.6% during the fourth quarter. BIP Wealth LLC now owns 1,249 shares of the medical research company’s stock worth $360,000 after acquiring an additional 32 shares during the last quarter. Southland Equity Partners LLC boosted its position in shares of Amgen by 2.3% during the fourth quarter. Southland Equity Partners LLC now owns 1,538 shares of the medical research company’s stock worth $443,000 after acquiring an additional 34 shares during the last quarter. Acropolis Investment Management LLC boosted its position in shares of Amgen by 3.5% during the fourth quarter. Acropolis Investment Management LLC now owns 999 shares of the medical research company’s stock worth $288,000 after acquiring an additional 34 shares during the last quarter. Opal Wealth Advisors LLC boosted its position in shares of Amgen by 1.9% during the fourth quarter. Opal Wealth Advisors LLC now owns 1,868 shares of the medical research company’s stock worth $538,000 after acquiring an additional 34 shares during the last quarter. Finally, Marino Stram & Associates LLC boosted its position in shares of Amgen by 0.7% during the fourth quarter. Marino Stram & Associates LLC now owns 4,626 shares of the medical research company’s stock worth $1,332,000 after acquiring an additional 34 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Oppenheimer restated an “outperform” rating and set a $350.00 target price on shares of Amgen in a research report on Thursday, February 1st. TD Cowen decreased their price target on shares of Amgen from $370.00 to $360.00 and set a “buy” rating on the stock in a research note on Wednesday, April 17th. Leerink Partnrs downgraded shares of Amgen from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 7th. The Goldman Sachs Group upped their price target on shares of Amgen from $313.00 to $350.00 and gave the company a “buy” rating in a research note on Wednesday, February 7th. Finally, Truist Financial reaffirmed a “buy” rating and set a $320.00 price target on shares of Amgen in a research note on Friday, April 12th. Ten analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $296.95.

Amgen Trading Up 0.2 %

Shares of AMGN opened at $269.98 on Friday. The company has a market cap of $144.81 billion, a P/E ratio of 21.62, a P/E/G ratio of 2.60 and a beta of 0.58. Amgen Inc. has a twelve month low of $211.71 and a twelve month high of $329.72. The company’s fifty day simple moving average is $275.10 and its 200-day simple moving average is $281.52. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 10.14.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, topping the consensus estimate of $4.66 by $0.05. The company had revenue of $8.20 billion for the quarter, compared to the consensus estimate of $8.13 billion. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The firm’s revenue was up 19.8% compared to the same quarter last year. During the same quarter last year, the firm posted $4.09 EPS. As a group, analysts expect that Amgen Inc. will post 19.43 EPS for the current year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be paid a $2.25 dividend. This represents a $9.00 annualized dividend and a yield of 3.33%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s dividend payout ratio is presently 72.06%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.